RenovoRx Inc
NASDAQ:RNXT
RenovoRx Inc
Other
RenovoRx Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
RenovoRx Inc
NASDAQ:RNXT
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
$45m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$440m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$10.9B
|
CAGR 3-Years
-372%
|
CAGR 5-Years
-161%
|
CAGR 10-Years
-34%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$366.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$542.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-5%
|
|
RenovoRx Inc
Glance View
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. The company is headquartered in San Jose, California and currently employs 6 full-time employees. The company went IPO on 2021-08-17. The firm is focused on developing therapies for the local treatment of solid tumors. The firm's lead product candidate RenovoGem. Its other product candidate include Renovo Trans-Arterial Micro-Perfusion (RenovoTAMP), and RenovoCath delivery system. RenovoGem, is a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. Its therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) is focused on optimizing drug concentration in solid tumors using small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy.
